Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study - final study results.

Autor: Makhema J; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, USA., Shava E; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Izu A; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Department of Science and Innovation, National Research Foundation South African Research Initiative in Vaccine Preventable Diseases Unit, University of the Witwatersrand, Johannesburg, South Africa., Gaolathe T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; Faculty of Medicine, University of Botswana, Gaborone, Botswana., Kuate L; Department of Health Systems Management, Clinical Services, Ministry of Health Botswana, Gaborone, Botswana., Walker A; Medical Evidence, Vaccine and Immune Therapies, BioPharmaceuticals Medicine, AstraZeneca, Cambridge, UK., Carty L; Medical and Payer Evidence Statistics, BioPharmaceuticals Medicine, AstraZeneca, Cambridge, UK., Georgiou P; Late Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Kgathi C; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Choga WT; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana., Sekoto T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Seonyatseng N; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Mogashoa T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Maphorisa CN; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Mohammed T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Ntalabgwe T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Frank TT; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Matlhaku B; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Diphoko A; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Phindela T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Kaunda A; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Kgari P; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Kanyakula T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Palalani G; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Phakedi I; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Mmalane M; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Taylor S; Infection Evidence Strategy, Vaccine and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Moyo S; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, USA.; School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.; School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.; Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Publikováno v: IJID regions [IJID Reg] 2023 Nov 10; Vol. 10, pp. 35-43. Date of Electronic Publication: 2023 Nov 10 (Print Publication: 2024).